Every 8-K that Immucell Corp (ICCC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ICCC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICCC filings page.
ImmuCell Corporation reported significantly improved results for the quarter ended June 30, 2026. Revenue grew 11.5% to $7.2 million, driven by higher distributor volumes and pricing, with distributor out-the-door volume up 28%. Net income rose to $1.8 million (basic and diluted EPS $0.20), compared to $0.5 million (EPS $0.06) a year earlier, aided by a $2.0 million one-time settlement from a former contract manufacturer, recorded as other operating income.
Gross margin was 34%, pressured by lower manufacturing volumes, scrap from a purchased material quality issue, and costs shifted from the discontinued Re-Tain® program. Adjusted EBITDA increased to $2.7 million from $1.4 million in the prior-year quarter. Cash and cash equivalents were $8.9 million as of June 30, 2026, up from $3.8 million at year-end, supported by $6.6 million of operating cash flow in the first half.
The company’s share of U.S. calves receiving a scour biological reached 19%. ImmuCell is executing a two-phase First Defense® capacity expansion, with planned investments of approximately $3.5 million in freeze-drying capacity and $4.5 million in colostrum processing, expected to be financed with cash on hand and cash from operations.
ImmuCell Corporation reported preliminary, unaudited sales showing strong growth in 2026. Total product sales for the three months ended June 30, 2026 were $7.2 million, up 11.5% from $6.4 million a year earlier, driven by a 27.7% increase in domestic sales to $6.2 million. International sales for the quarter declined to $1.0 million from $1.6 million, a 38.9% decrease. For the first six months of 2026, total product sales reached $17.5 million, a 20.9% increase compared to $14.5 million in 2025, with domestic sales of $16.0 million and international sales of $1.6 million. Product-wise, Q2 2026 Tri-Shield First Defense sales were $4.9 million, up 8.3%, while Dual-Force and other sales were $2.3 million, up 19.1%. Management plans to discuss full financial results on a conference call on August 14, 2026.
ImmuCell Corporation held its 2026 annual stockholder meeting by webcast and conference call, with 7,397,695 common shares present, representing more than 81% of eligible votes. Stockholders elected seven directors to one-year terms, each receiving over 5.16 million votes in favor with relatively few votes withheld.
Investors approved a non-binding advisory resolution on executive compensation, with 4,793,553 votes for and 92.4% of votes cast in favor. Another stockholder matter was also approved with 4,689,407 votes for and 90.39% support among votes cast. Stockholders approved an amendment to the Certificate of Incorporation regarding officer exculpation, receiving 4,851,019 votes for, which represented 53.62% of total shares outstanding.
They also ratified the Audit Committee’s selection of Wipfli LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 7,344,196 votes for, 14,645 against and 38,854 abstentions, reflecting 99.28% support among votes cast.
ImmuCell Corporation outlined a manufacturing capacity expansion focused on its flagship First Defense® product line. The Board authorized a program that shifts resources away from the previously planned in-house Re-Tain® production toward expanded First Defense® output.
The first phase will start immediately, renovating the former Re-Tain® facility and installing a new, higher-capacity freeze dryer. This phase is expected to take about 12 months and cost approximately $3.5 million. A second phase will repurpose additional Re-Tain® equipment and add automation to further expand First Defense® colostrum processing, with the goal of reliably meeting expected customer demand.
ImmuCell Corporation reported strong first-quarter 2026 results, highlighted by double-digit growth and improved profitability. Product sales rose 28.4% to $10.4 million, lifting gross margin to 45.0%. Net income increased to $1.9 million, or $0.21 per share, compared with $1.4 million, or $0.16 per share, a year earlier.
The company generated $3.4 million of free cash flow, raising cash to $6.8 million as of March 31, 2026, while maintaining solid inventory. ImmuCell also received a net $2 million payment from settling disputes with a former contract manufacturer and increased manufacturing output from about 380,000 to more than 450,000 units per month.
ImmuCell Corporation entered into a new settlement agreement with Norbrook Laboratories on May 8, 2026. The companies signed a Settlement Deed that resolves and releases all claims related to their 2019 Development Services and Commercial Supply Agreement, which expired March 31, 2026. Under this Settlement Deed, Norbrook will pay ImmuCell $2,000,000, providing a one-time cash benefit to ImmuCell. The agreement is governed by Northern Ireland law, contains confidentiality undertakings, and explicitly states it is not an admission of liability or wrongdoing by either party.
ImmuCell Corporation announced significant Board changes and governance updates. Three long-serving directors, including former President and CEO Michael Brigham and Vice President of Sales and Marketing Bobbi Jo Brockmann, will retire from the Board effective April 15, 2026, while remaining executives where applicable.
The Company appointed two new directors, Dr. Gilles Guillemette and Dr. Anthony DiMarco, both with extensive animal health and biologics experience. ImmuCell is moving to a 7-person Board with six Independent Directors and the CEO, and is creating a new Strategy and Technology Committee to support innovation and manufacturing improvements.
ImmuCell Corporation reported strong preliminary sales growth for the first quarter of 2026. Total product sales for the three months ended March 31, 2026 were $10.4 million, up from $8.1 million a year earlier, a 28.4% increase. Growth was driven mainly by Tri-Shield® First Defense®, which generated $7.9 million in sales, a 38.5% increase compared to the prior-year period.
Domestic sales were $9.7 million, up 35.7%, while international sales declined to $0.6 million, down 30.2%. Management cited strong seasonal demand from the cow-calf segment and improved inventory and manufacturing strategies, while noting that previous backlogs still complicate growth comparisons.
ImmuCell Corporation announced a planned Board transition. Longtime director Steven A. Rosgen tendered his resignation effective April 1, 2026, after previously indicating he would not stand for re‑election. To fill the vacancy, the Board elected Kathy V. Turner, also effective April 1, 2026.
Ms. Turner brings more than three decades of commercial leadership in global healthcare and animal health, including senior roles at IDEXX Laboratories and nearly 30 years at Abbott Laboratories. She previously served on Elanco Animal Health’s Board and currently serves on the Board of Veterinarians Without Borders.
Upon joining, she will chair ImmuCell’s Compensation and Stock Option Committee and serve on the Audit Committee. ImmuCell highlighted her experience supporting growth of its First Defense® product line and thanked Mr. Rosgen for eight years of service.
ImmuCell Corporation reported unaudited 2025 results showing a return to profitability at the operating level and a narrower bottom-line loss. Net operating income was $1.6 million, an improvement of $3.3 million from 2024, driven by stronger gross margins from higher volumes, manufacturing efficiencies and pricing.
Full-year product sales rose 4.3% to $27.6 million, while gross profit increased to $11.4 million from $7.9 million. Despite several non‑recurring charges, including a $2.7 million Re‑Tain® write‑down and $651,000 of colostrum inventory write‑downs, net loss improved to $1.0 million from $2.2 million. EBITDA nearly doubled to $2.2 million. Year-end cash was $3.8 million with positive operating cash flow of $2.5 million, and management highlighted a strategic focus on its First Defense® franchise.
ImmuCell Corporation reported that two directors, Steven A. Rosgen and Bryan K. Gathagan, have each notified the company that they prefer not to run for re-election at the 2026 Annual Meeting of Shareholders. Both directors are described as supportive of the company’s new strategic direction and management team, but cited time constraints from full-time leadership roles at their own companies. The Board’s Nominating Committee has been reviewing possible changes to Board composition and will now incorporate these planned retirements into its ongoing work.
ImmuCell Corporation updated compensation arrangements for key executives. Effective January 27, 2026, new employment agreements set annual base salaries of $315,000 for CFO Timothy C. Fiori and $300,000 for Senior VP of Sales and Marketing Bobbi Jo Brockmann. Beginning with the fiscal year ending December 31, 2026, each can earn a formula-based annual cash bonus targeting 50% of base salary, rising to 60% if preset financial and strategic targets are exceeded by at least 20%. The Compensation and Stock Option Committee also granted Fiori an option for 120,000 shares and Brockmann an option for 100,000 shares under the 2025 Stock Option and Incentive Plan, vesting in three equal annual installments from January 2027 at an exercise price of $6.26 per share, with potential accelerated vesting upon a change of control or certain terminations. CEO Olivier te Boekhorst received a performance-based option for 110,000 shares at $6.26 per share, vesting only if net operating income for four consecutive quarters reaches at least 300% of audited 2025 net operating income.
ImmuCell Corporation reported that it has released preliminary, unaudited sales results for the three‑month and twelve‑month periods ended December 31, 2025, via a January 8, 2026 press release. The company also disclosed that it will record approximately $3.6 million in non‑cash impairment write‑downs for the quarter ended December 31, 2025, and stated it does not expect these charges to lead to material future cash expenditures, although actual amounts may differ from current estimates.
The company highlighted a strategic shift toward its First Defense® product line and away from Re‑Tain®, and scheduled a conference call on January 9, 2026 to discuss top‑line results and this shift. A second conference call is planned for February 26, 2026 to review full, unaudited financial results for the quarter and year ended December 31, 2025, which the company expects to release after market close on February 25, 2026.
ImmuCell Corporation furnished an 8-K announcing it issued a press release with unaudited financial results for the quarter ended September 30, 2025. The disclosure is under Item 2.02 and is expressly stated as furnished, not filed, which limits liability under Section 18.
The filing includes Exhibit 99.1 (press release dated November 13, 2025) and Exhibit 104 (cover page Inline XBRL).
ImmuCell Corporation announced governance changes tied to its CEO transition. Effective November 1, 2025, Olivier te Boekhorst became President and CEO, while Michael F. Brigham stepped down from his roles as President, CEO, Secretary, and Treasurer to serve as Special Advisor to the CEO. On October 29, 2025, the Board expanded from seven to nine directors and elected Mr. te Boekhorst and CFO Timothy C. Fiori as directors. Mr. Fiori was also elected Secretary and Treasurer. Neither executive was appointed to any Board committees.
ImmuCell Corporation filed a current report to let investors know it has released preliminary, unaudited product sales figures for the quarter ended September 30, 2025. The company communicated these early sales results through a press release dated October 7, 2025, which is included as Exhibit 99.1 to the report. The exhibit is designated as “furnished” rather than “filed,” meaning it is provided for information purposes under securities rules without being incorporated into other filings unless specifically referenced.
ImmuCell Corporation appointed Olivier te Boekhorst as President and CEO effective November 1, 2025. He joins from Archimed and previously held senior roles at IDEXX Laboratories and Boston Consulting Group. His compensation package includes a $450,000 base salary, up to $400,000 annual cash bonus tied to financial improvement targets, a $100,000 one-time signing bonus (repayable in certain circumstances), and initial equity awards: a nonqualified option for 76,673 shares at $5.90 and a second grant of up to 85,000 shares (accounting value $250,000). Equity awards vest over three years and accelerate on a Change in Control. The Board will expand and elect him as a director. The existing CEO will transition to Special Advisor during a handover period.
ImmuCell Corporation entered into an Allonge to and Amendment of its existing line of credit with Maine Community Bank. This agreement extends the Company’s $1 million line of credit through September 11, 2026, allowing continued access to this borrowing capacity.
Borrowings under the line of credit will bear interest at a variable rate equal to the National Prime Rate per annum. The extension represents an ongoing banking relationship rather than a new borrowing and is documented as a material definitive agreement and direct financial obligation.
ImmuCell Corporation entered into a Loan Agreement and Promissory Note with Maine Community Bank for total loan proceeds of $2,327,119 at a fixed interest rate of 6.5% per annum. The proceeds were used to pay off an existing Maine Community Bank loan with an outstanding balance of $1,525,852 bearing interest at 7% and a Finance Authority of Maine loan with an outstanding balance of $768,209 bearing interest at 8%, effectively consolidating those obligations into a single loan.
The new loan is secured by a security interest in substantially all of the Company’s assets, and the lender may accelerate repayment if the Company fails to make timely payments or otherwise comply with the loan terms. The Loan Agreement and Promissory Note are filed as Exhibits 10.1 and 10.2, and a related press release is filed as Exhibit 99.1.
ImmuCell Corporation (NASDAQ:ICCC) filed an 8-K announcing the initiation of a CEO succession planning process. The filing discloses that current President and CEO Michael F. Brigham will be part of this transition. The company has begun searching for new leadership, though no specific timeline was provided. This represents a significant corporate governance development for ImmuCell, as leadership transitions can materially impact company strategy and operations.